Clinical Trials
6
Active:0
Completed:5
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (50.0%)Phase 1
2 (33.3%)Early Phase 1
1 (16.7%)Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers
Phase 2
- Conditions
- Malaria, Vivax
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Malaria Vaccine and Drug Development Center
- Target Recruit Count
- 120
- Registration Number
- NCT04739917
- Locations
- 🇨🇴
Malaria Vaccine and Drug Development Center, Cali, Valle Del Cauca, Colombia
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Phase 2
Completed
- Conditions
- Malaria
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Malaria Vaccine and Drug Development Center
- Target Recruit Count
- 32
- Registration Number
- NCT02083068
- Locations
- 🇨🇴
Malaria Vaccine and Drug Development Center, Cali, Valle Del Cauca, Colombia
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
Early Phase 1
Completed
- Conditions
- Malaria, Vivax
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Malaria Vaccine and Drug Development Center
- Target Recruit Count
- 18
- Registration Number
- NCT01083095
- Locations
- 🇨🇴
Malaria Vaccine and Drug Testing Center, Cali, Valle, Colombia
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
Phase 1
Completed
- Conditions
- Malaria
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Malaria Vaccine and Drug Development Center
- Target Recruit Count
- 27
- Registration Number
- NCT01082341
- Locations
- 🇨🇴
Malaria Vaccine of Develepmente Center, Cali, Valle, Colombia
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Phase 1
Completed
- Conditions
- Malaria, Vivax
- Interventions
- Drug: Peptides (N,R&C) formulated in Montanide ISA 51Drug: Peptides (N,R&C) formulated in Montanide ISA 720Other: Placebo
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Malaria Vaccine and Drug Development Center
- Target Recruit Count
- 40
- Registration Number
- NCT01081847
- Locations
- 🇨🇴
Malaria Vaccine and Drug Testing Center, Cali, Valle, Colombia
🇨🇴Malaria Vaccine of Develepmente Center, Cali, Valle, Colombia
- Prev
- 1
- 2
- Next
News
No news found